Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 20/20 | 0.80 |
| ▸ | MAPK12 | P53778 | 20/20 | 0.80 |
| ▸ | MAPK11 | Q15759 | 20/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045380 | 0.90 | MAPK13 (0.81) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4047059 | 0.90 | MAPK13 (0.76) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4048233 | 0.90 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4051233 | 0.89 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4044440 | 0.88 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4052277 | 0.88 | MAPK13 (0.72) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4050824 | 0.87 | MAPK13 (0.90) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4046519 | 0.86 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4045582 | 0.84 | MAPK13 (0.81) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4043034 | 0.83 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539761-B1 | 6,7-DIHYDRO-5H-PYRAZOLO¬1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1539761-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A] PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6849627-B2 | Including interleukin-1 and Tumor Necrosis Factor; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, septic shock, cardiopulmonary dysfunction, acute respiratory disease, and cachexia | THE PROCTER & GAMBLE COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| WO-2004026878-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-a]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040038971-A1 | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038971-A1 | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | IL1B, IL1A, IL6 | MAPK13 2320/4885MAPK12 1929/4885MAPK11 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.